Vera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $114,351 | $354,725 |
| Marketable securities | 482,409 | 359,864 |
| Prepaid expenses and other assets, current | 19,042 | 14,294 |
| Total current assets | 615,802 | 728,883 |
| Other assets, noncurrent | 5,937 | 5,850 |
| Total assets | $621,739 | $734,733 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,909 | $21,898 |
| Accrued expenses and other liabilities, current | 31,240 | 31,557 |
| Total current liabilities | 45,149 | 53,455 |
| Long-term debt | 75,029 | 74,838 |
| Other liabilities, noncurrent | 1,864 | 1,919 |
| Total liabilities | 122,042 | 130,212 |
| Stockholders’ equity | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,730,090 and 71,267,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 72 | 71 |
| Additional paid-in capital | 1,381,678 | 1,364,529 |
| Accumulated other comprehensive (loss) income | (156) | 786 |
| Accumulated deficit | (881,897) | (760,865) |
| Total stockholders’ equity | 499,697 | 604,521 |
| Total liabilities and stockholders’ equity | $621,739 | $734,733 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.